- Home
- VCYT
VCYT
Veracyte Inc.
as 01-17-2025 4:00pm EST
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.2B | IPO Year: | 2013 |
| Target Price: | $39.86 | AVG Volume (30 days): | 807.5K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.61 - $46.00 | Next Earning Date: | 02-20-2025 |
| Revenue: | $425,331,000 | Revenue Growth: | 23.95% |
| Revenue Growth (this year): | 25.25% | Revenue Growth (next year): | 10.05% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EASTHAM KARIN | VCYT | Director | Jan 2 '25 | Sell | $40.31 | 10,000 | $403,005.64 | 18,497 | |
| Stapley Marc | VCYT | Chief Executive Officer | Dec 13 '24 | Sell | $43.75 | 5,590 | $242,736.96 | 307,345 | |
| McGuire Annie | VCYT | SVP, General Counsel | Dec 4 '24 | Sell | $44.02 | 18,699 | $823,178.60 | 72,869 | |
| Febbo Phillip G. | VCYT | Chief Scientific & Med Officer | Dec 4 '24 | Sell | $44.09 | 3,934 | $173,447.31 | 82,414 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Dec 2 '24 | Sell | $43.23 | 7,000 | $302,621.90 | 114,037 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Dec 2 '24 | Sell | $43.25 | 1,050 | $45,407.88 | 73,810 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Dec 2 '24 | Sell | $43.36 | 956 | $41,452.45 | 40,270 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Nov 27 '24 | Sell | $42.89 | 5,032 | $215,833.55 | 40,270 | |
| EASTHAM KARIN | VCYT | Director | Nov 19 '24 | Sell | $37.76 | 14,731 | $564,768.40 | 18,497 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Nov 12 '24 | Sell | $38.34 | 15,275 | $585,663.36 | 114,037 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
Simply Wall St.
9 days ago
Veracyte, Inc. (NASDAQ:VCYT) Has Found A Path To Profitability
Zacks
12 days ago
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
Zacks
13 days ago
Veracyte Gains 44% in a Year: What's Driving the Stock?
Zacks
16 days ago
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down
Zacks
16 days ago
Phibro Animal Health Gains 83% in a Year: What's Driving the Stock?
Zacks
16 days ago
Should You Retain Labcorp Stock in Your Portfolio Right Now?
Zacks
23 days ago
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.